Abstract
Non-Hodgkin’s lymphomas (NHLs) are a heterogeneous group of malignant lymphomas that can occur in both lymph nodes and extranodal sites. Bone marrow (BM) is the most common site of extranodal involvement in NHL. The objective of this study is to determine the unique profile of miRNA expression in BM affected by NHL, with the possibility of a differential diagnosis of NHL from reactive BM changes and acute leukemia (AL). A total of 180 cytological samples were obtained by sternal puncture and aspiration biopsy of BM from the posterior iliac spine. All the cases were patients before treatment initiation. The study groups were NHL cases (n = 59) and AL cases (acute lymphoblastic leukemia (n = 25) and acute myeloid leukemia (n = 49)); the control group consisted of patients with non-cancerous blood diseases (NCBDs) (n = 48). We demonstrated that expression levels of miRNA-124, miRNA-221, and miRNA-15a are statistically significantly downregulated, while the expression level of let-7a is statistically significantly upregulated more than 2-fold in BM in NHL compared to those in AL and NCBD. ROC analysis revealed that let-7a/miRNA-124 is a highly sensitive and specific biomarker for a differential diagnosis of BM changes in NHL from those in AL and NCBD. Therefore, we conclude that analysis of miRNA expression levels may be a promising tool for early diagnosis of NHL.
Highlights
Non-Hodgkin’s lymphoma (NHL) is a lymphoid tissue neoplasm arising from B cell precursors, mature B cells, T cell precursors, and mature T and NK cells
MiRNA expression levels were measured by RT-qPCR in the NHL, acute leukemia (AL), and non-cancerous blood diseases (NCBDs) groups (Figure 1)
A comparative analysis of miRNA expression dleovwelnsrbeegtuwlaeteendthine ANLH(Lp a
Summary
Non-Hodgkin’s lymphoma (NHL) is a lymphoid tissue neoplasm arising from B cell precursors, mature B cells, T cell precursors, and mature T and NK cells. NHLs are a heterogeneous group of lymphoproliferative malignancies that can occur both in lymph nodes and in extranodal sites [1]. One of the IPI variables is assessing the status of bone marrow hematopoiesis. Bone marrow (BM) is the most common site of extranodal involvement in malignant lymphoid neoplasms [3]. BM lesions can be detected using non-invasive diagnostic methods such as MRI and PET-CT, but BM biopsy is indicated if PET/CT is negative; in some clinical situations, BM biopsy can be the only technique providing data on the presence and degree of BM infiltration with tumor lymphoid cells [5–7]. Aspiration cytology and trephine biopsy are believed to complement each other and increase the accuracy of NHL diagnosis [8,9]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
